Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ALLEGRA ALLERGY versus CLARINEX D 12 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ALLEGRA ALLERGY versus CLARINEX D 12 HOUR.
CHILDREN'S ALLEGRA ALLERGY vs CLARINEX-D 12 HOUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine release from mast cells and basophils, reducing allergic symptoms.
Desloratadine is a long-acting tricyclic histamine antagonist selective for H1-receptor with additional anti-inflammatory properties. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors.
Fexofenadine 60 mg orally twice daily or 180 mg once daily.
1 tablet (5 mg desloratadine / 120 mg pseudoephedrine) orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 14.4 hours (range 11–17 hours) in healthy adults. In children aged 6–12 years, half-life is similar. Clinical context: allows once-daily dosing.
Desloratadine: 27 hours (terminal), allows once-daily dosing; pseudoephedrine: 4-6 hours (prolonged in alkaline urine).
Fexofenadine is excreted primarily unchanged in feces (approximately 80%) and urine (approximately 11%). Biliary excretion accounts for a minor portion.
Desloratadine: 40.2% renal (unchanged and metabolites), 41.7% fecal; pseudoephedrine: 70-90% renal (unchanged).
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination